Trial reportJournal of pharmacokinetics and pharmacodynamics2005
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.
Trial report in Journal of pharmacokinetics and pharmacodynamics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.CPT: pharmacometrics & systems pharmacology · 2026Article
- Article
- Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.Clinical pharmacokinetics · 2016Article
- Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.Clinical pharmacokinetics · 2016Article
- Simultaneous optimal experimental design for in vitro binding parameter estimation.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.Pharmaceutical research · 2012Article
- Optimal study design for pioglitazone in septic pediatric patients.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria.Malaria journal · 2011Article
- Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.British journal of clinical pharmacology · 2011Review
- Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.Clinical pharmacokinetics · 2010Article
- D-optimal designs for parameter estimation for indirect pharmacodynamic response models.Journal of pharmacokinetics and pharmacodynamics · 2009Article
- Towards optimal design of anti-malarial pharmacokinetic studies.Malaria journal · 2009Article
- Simultaneous optimal experimental design on dose and sample times.Journal of pharmacokinetics and pharmacodynamics · 2009Article
- Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.Clinical pharmacokinetics · 2009Review
- Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.British journal of clinical pharmacology · 2008Article
- Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.Journal of pharmacokinetics and pharmacodynamics · 2007Article
- A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.British journal of clinical pharmacology · 2007Article
- Some considerations on the design of population pharmacokinetic studies.Journal of pharmacokinetics and pharmacodynamics · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal sampling times are found for a study in which one of the primary purposes is to develop a model of the pharmacokinetics of itraconazole in patients with cystic fibrosis for both capsule and solution doses. The optimal design is expected to produce reliable estimates of population parameters for two different structural PK models. Data collected at these sampling times are also expected to provide the researchers with sufficient information to reasonably discriminate between the two competing structural models.
Indexed as
Identifiers
16307208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.